231 related articles for article (PubMed ID: 26621323)
1. Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.
Dhalla F; Fox H; Davenport EE; Sadler R; Anzilotti C; van Schouwenburg PA; Ferry B; Chapel H; Knight JC; Patel SY
Clin Exp Immunol; 2016 May; 184(2):216-27. PubMed ID: 26621323
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of two STAT1 gain-of-function mutations in two Iranian families with autosomal dominant chronic mucocutaneous candidiasis.
Ostadi V; Sherkat R; Migaud M; Modaressadeghi SM; Casanova JL; Puel A; Nekooie-Marnany N; Ganjalikhani-Hakemi M
Med Mycol; 2021 Feb; 59(2):180-188. PubMed ID: 32526033
[TBL] [Abstract][Full Text] [Related]
3. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
Egri N; Esteve-Solé A; Deyà-Martínez À; Ortiz de Landazuri I; Vlagea A; García AP; Cardozo C; Garcia-Vidal C; Bartolomé CS; Español-Rego M; Yiyi L; Bosch-Amate X; Ferrando J; Yagüe J; Juan M; Alsina L
Allergol Immunopathol (Madr); 2021; 49(1):118-127. PubMed ID: 33528939
[TBL] [Abstract][Full Text] [Related]
4. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22.
Eyerich K; Foerster S; Rombold S; Seidl HP; Behrendt H; Hofmann H; Ring J; Traidl-Hoffmann C
J Invest Dermatol; 2008 Nov; 128(11):2640-2645. PubMed ID: 18615114
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.
Rösler B; Wang X; Keating ST; Joosten LAB; Netea MG; van de Veerdonk FL
Clin Exp Immunol; 2018 Nov; 194(2):205-219. PubMed ID: 30069986
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Disseminated
Chen K; Tan J; Qian S; Wu S; Chen Q
Front Immunol; 2021; 12():682350. PubMed ID: 34421897
[TBL] [Abstract][Full Text] [Related]
7. Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel
Erdős M; Jakobicz E; Soltész B; Tóth B; Bata-Csörgő Z; Maródi L
Front Immunol; 2020; 11():967. PubMed ID: 32547544
[TBL] [Abstract][Full Text] [Related]
8. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B; Lambourne J; Porter S; Hodgson T
Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
[TBL] [Abstract][Full Text] [Related]
9. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
10. Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis.
Ifrim DC; Quintin J; Meerstein-Kessel L; Plantinga TS; Joosten LA; van der Meer JW; van de Veerdonk FL; Netea MG
Clin Exp Immunol; 2015 Sep; 181(3):434-40. PubMed ID: 25880788
[TBL] [Abstract][Full Text] [Related]
11. A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis.
Nielsen J; Kofod-Olsen E; Spaun E; Larsen CS; Christiansen M; Mogensen TH
BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26494717
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
[TBL] [Abstract][Full Text] [Related]
13. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
van de Veerdonk FL; Plantinga TS; Hoischen A; Smeekens SP; Joosten LA; Gilissen C; Arts P; Rosentul DC; Carmichael AJ; Smits-van der Graaf CA; Kullberg BJ; van der Meer JW; Lilic D; Veltman JA; Netea MG
N Engl J Med; 2011 Jul; 365(1):54-61. PubMed ID: 21714643
[TBL] [Abstract][Full Text] [Related]
14. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.
Depner M; Fuchs S; Raabe J; Frede N; Glocker C; Doffinger R; Gkrania-Klotsas E; Kumararatne D; Atkinson TP; Schroeder HW; Niehues T; Dückers G; Stray-Pedersen A; Baumann U; Schmidt R; Franco JL; Orrego J; Ben-Shoshan M; McCusker C; Jacob CM; Carneiro-Sampaio M; Devlin LA; Edgar JD; Henderson P; Russell RK; Skytte AB; Seneviratne SL; Wanders J; Stauss H; Meyts I; Moens L; Jesenak M; Kobbe R; Borte S; Borte M; Wright DA; Hagin D; Torgerson TR; Grimbacher B
J Clin Immunol; 2016 Jan; 36(1):73-84. PubMed ID: 26604104
[TBL] [Abstract][Full Text] [Related]
15. [Chronic mucocutaneous candidiasis with STAT1 gain-of-function mutation associated with herpes virus and mycobacterial infections].
Baghad B; Benhsaien I; El Fatoiki FZ; Migaud M; Puel A; Chiheb S; Bousfiha AA; Ailal F
Ann Dermatol Venereol; 2020 Jan; 147(1):41-45. PubMed ID: 31677808
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
Liu L; Okada S; Kong XF; Kreins AY; Cypowyj S; Abhyankar A; Toubiana J; Itan Y; Audry M; Nitschke P; Masson C; Toth B; Flatot J; Migaud M; Chrabieh M; Kochetkov T; Bolze A; Borghesi A; Toulon A; Hiller J; Eyerich S; Eyerich K; Gulácsy V; Chernyshova L; Chernyshov V; Bondarenko A; Grimaldo RM; Blancas-Galicia L; Beas IM; Roesler J; Magdorf K; Engelhard D; Thumerelle C; Burgel PR; Hoernes M; Drexel B; Seger R; Kusuma T; Jansson AF; Sawalle-Belohradsky J; Belohradsky B; Jouanguy E; Bustamante J; Bué M; Karin N; Wildbaum G; Bodemer C; Lortholary O; Fischer A; Blanche S; Al-Muhsen S; Reichenbach J; Kobayashi M; Rosales FE; Lozano CT; Kilic SS; Oleastro M; Etzioni A; Traidl-Hoffmann C; Renner ED; Abel L; Picard C; Maródi L; Boisson-Dupuis S; Puel A; Casanova JL
J Exp Med; 2011 Aug; 208(8):1635-48. PubMed ID: 21727188
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
18. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody.
Yamazaki Y; Yamada M; Kawai T; Morio T; Onodera M; Ueki M; Watanabe N; Takada H; Takezaki S; Chida N; Kobayashi I; Ariga T
J Immunol; 2014 Nov; 193(10):4880-7. PubMed ID: 25288569
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis.
Kisand K; Peterson P
Curr Opin Pediatr; 2013 Dec; 25(6):715-21. PubMed ID: 24240291
[TBL] [Abstract][Full Text] [Related]
20. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S; Asano T; Moriya K; Boisson-Dupuis S; Kobayashi M; Casanova JL; Puel A
J Clin Immunol; 2020 Nov; 40(8):1065-1081. PubMed ID: 32852681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
